Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation

Current Pharmaceutical Biotechnology

Volumn 14, Issue 15, 2013, Pages 1287-1298

  Ye, Xianlong ^a   Qi, Jianying ^a   Sun, Guopeng ^b   Ren, Guiping ^a   Zhu, Shenglong ^a   Wu, Yunzhou ^a   Yu, Dan ^a   Zhao, Jingzhuang ^c   Liu, Mingyao ^a   Li, Deshan ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b XINXIANG UNIVERSITY   (China)

^c SOUTH CHINA SEA FISHERIES RESEARCH INSTITUTE   (China)

Author keywords

Diabetes; FGF 21; Genetic modification; Immunogenicity; PEGylation; Stability

Indexed keywords

AHM FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL; PEGYLATED AHM FIBROBLAST GROWTH FACTOR 21; RECOMBINANT PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIBODY; ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD ANALYSIS; CONTROLLED STUDY; DNA MODIFICATION; DNA SEQUENCE; DRUG STABILITY; GEL FILTRATION CHROMATOGRAPHY; GENETIC ANALYSIS; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; ANIMAL; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; GENETICS; HEPG2 CELL LINE; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; RABBIT;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; GLUCOSE; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MUTATION; POLYETHYLENE GLYCOLS; PROTEIN STRUCTURE, TERTIARY; RABBITS;

EID: 84921871482     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140515124838     Document Type: Article

References (47)

1. [1] Nishimura, T.; Nakatake, Y.; Konishi, M.; Itoh, N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochimic. Biophysic. Acta, 2000, 1492(1), 203-206.
2. [2] Itoh, N.; Ornitz, D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet., 2004, 20(11), 563-569.
3. [3] Beenken, A; Mohammadi, M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov., 2009, 8(3), 235-253.
4. [4] Kharitonenkov, A.; Shiyanova, T.L.; Koester, A.; Ford, A.M.; Micanovic, R.; Galbreath, E.J.; Sandusky, G.E.; Hammond, L.J.; Moyers, J.S.; Owens, R.A.; Gromada, J.; Brozinick, J.T.; Hawkins, E.D.; Wroblewski, V.J.; Li, D.S.; Mehrbod, F.; Jaskunas, S.R.; Shanafelt, A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest., 2005, 115(6), 1627-1635.
5. [5] Liu, M.Y.; Wang, W.F.; Yu, Y.X.; Hou, Y.T.; Ren, G.P.; Li, D.S. FGF21 improves glucose uptake and glycogen synthesis of insulinresistant liver cells. Prog. Biochem. Biophys., 2009, 36(10), 1327-1333.
6. [6] Kharitonenkov, A.; Wroblewski, V.J.; Koester, A.; Chen, Y.F.; Clutinger, C.K.; Tigno, X.T.; Hansen, B.C.; Shanafelt, A.B.; Etgen, G.J. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007, 148(2), 774-781.
7. [7] Wente, W.; Efanov, A.M.; Brenner, M.; Kharitonenkov, A.; Köster, A.; Sandusky, G.E.; Sewing, S.; Treinies, I.; Zitzer, H.; Gromada, J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes, 2006, 55(9), 2470-2478.
8. [8] Huang, X.; Yu, C.; Jin, C.; Yang, C.; Xie, R.; Cao, D.; Wang, F; McKeehan, W.L. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol. Carcinog., 2006, 45(12), 934-943.
9. [9] Huang, Z.; Wang, H.; Lu, M.; Sun, C.; Wu, X.; Tan, Y.; Ye, C.; Zhu, G.; Wang, X.; Cai, L.; Li, X. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. Plos One, 2011, 6(6), e20669.
10. [10] Yao, W.B.; Ren, G.P.; Han, Y.; Cao, H.W.; Gao, H.M.; Kan, F.M.; Wang, Q.; Li, D.S. Expression and pharmacological evaluation of fusion protein FGF21-L-Fc. Acta Pharm. Sin., 2011, 46(7), 787-792.
11. [11] Ye, X.L.; Gao, H.S.; Wang, W.F.; Ren, G.P.; Liu, M.Y.; He, K.; Zhang, Y.K.; Zhao, J.Z.; Yu, D.; Li, D.S. Optimization and characterization of a novel FGF21 mutant. Acta Pharm. Sin., 2012, 47(7), 897-903.
12. [12] Wang, H.; Xiao, Y.; Fu, L.; Zhao, H.; Zhang, Y.; Wan, X.; Qin, Y.; Huang, Y.; Gao, H.; Li, X. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol., 2010, 10, 14.
13. [13] Lee, B.K.; Kwon, J.S.; Kim, H.J.; Yamamoto, S.; Lee, E.K. Solidphase PEGylation of recombinant interferon alpha-2a for sitespecific modification: process performance, characterization, and in vitro bioactivity. Bioconjug. Chem., 2007, 18(6), 1728-1734.
14. [14] Mukai, Y.; Yoshioka, Y.; Tsutsumi, Y. Phage display and PEGylation of therapeutic proteins. Comb. Chem. High Throughput Screen., 2005, 8(2), 145-152.
15. [15] Yoshioka, Y.; Tsutsumi, Y.; Nakagawa, S.; Mayumi, T. Recent progress on tumor missile therapy and tumor vascular targeting therapy as a new approach. Curr. Vasc. Pharmacol., 2004, 2(3), 259-270.
16. [16] Roberts, M.J.; Bentley, M.D.; Harris, J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliver. Rev., 2002, 54(4), 459-476.
17. [17] Narimatsu, S.; Yoshioka, Y.; Watanabe, H.; Masano, T.; Morishige, T.; Yao, X.; Tanabe, A.; Tsunoda, S.; Tsutsumi, Y.; Mukai, Y.; Okada, N.; Nakagawa, S. Lysine-deficient lymphotoxin-alpha mutant for site-specific PEGylation. Cytokine, 2011, 56(2), 489-493.
18. [18] Mezo, A.R.; Low, S.C.; Hoehn, T.; Palmieri, H. PEGylation enhances the therapeutic potential of peptide antagonists of the neonatal Fc receptor, FcRn. Bioorg. Med. Chem. Lett., 2011, 21(21), 6332-6335.
19. [19] Yoshioka, Y.; Tsutsumi, Y.; Ikemizu, S.; Yamamoto, Y.; Shibata, H.; Nishibata, T.; Mukai, Y.; Okamoto, T.; Taniai, M.; Kawamura, M.; Abe, Y.; Nakagawa, S.; Nagata, S.; Yamagata, Y.; Mayumi, T. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency. Biochem. Biophys. Res. Commun., 2004, 315(4), 808-814.
20. [20] Marsac, Y.; Cramer, J.; Olschewski, D.; Alexandrov, K.; Becker, C.F. Site-specific attachment of polyethylene glycol-like oligomers to proteins and peptide. Bioconjug. Chem., 2006, 17(6), 1492-1498.
21. [21] Xiao, J.; Burn, A.; Tolbert, T.J. Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjug. Chem., 2008, 19(6), 1113-1118.
22. [22] Ye, X.L.; Zhao, J.Z.; Ren, G.P.; Yu, D.; Liu, M.Y.; Yu, Y.H.; Li, D.S. The hypoglycemic effect of the PEGylated FGF-21. Prog. Biochem. Biophys., 2013, 40(4), 374-385.
23. [23] Huang, Z.; Zheng, Q.; Wu, X.; Su, Z.; Xu, H.; Tan, Y.; Feng, W.; Li, X.; Cai, L. Enhanced protection of modified human acidic fibroblast growth factor with polyethylene glycol against ischemia/ reperfusion-induced retinal damage in rats. Toxicol. Lett., 2007, 170(2), 146-156.
24. [24] Goetz, R.; Beenken, A.; Ibrahimi, O.A.; Kalinina, J.; Olsen, S.K.; Eliseenkova, A.V.; Xu, C.; Neubert, T.A.; Zhang, F.; Linhardt, R.J.; Yu, X.; White, K.E.; Inagaki, T.; Kliewer, S.A.; Yamamoto, M.; Kurosu, H.; Ogawa, Y.; Kuro-o, M.; Lanske, B.; Razzaque, M.S.; Mohammadi, M. Molecular insights into the klothodependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell Biol., 2007, 27(9), 3417-3428.
25. [25] Zhang, X.; Ibrahimi, O.A.; Olsen, S.K.; Umemori, H.; Mohammadi, M.; Ornitz, D.M. Receptor specificity of the fi broblast growth factor family. The complete mammalian FGF family. J. Biol. Chem., 2006, 281(23), 15694-15700.
26. [26] Mu, J.; Pinkstaff, J.; Li, Z.; Skidmore, L.; Li, N.; Myler, H.; Dallas- Yang, Q.; Putnam, A.M.; Yao, J.; Bussell, S.; Wu, M.; Norman, T.C.; Rodriguez, C.G.; Kimmel, B.; Metzger, J.M.; Manibusan, A.; Lee, D.; Zaller, D.M.; Zhang, B.B.; DiMarchi, R.D.; Berger, J.P.; Axelrod, D.W. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes, 2012, 61(2), 505-512.
27. [27] Kharitonenkov, A.; Shanafelt, A.B. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs, 2008, 22(1), 37-44.
28. [28] Xu, J.; Lloyd, D.J.; Hale, C.; Stanislaus, S.; Chen, M.; Sivits, G.; Vonderfecht, S.; Hecht, R.; Li, Y.S.; Lindberg, R.A.; Chen, J.L.; Jung, D.Y.; Zhang, Z.; Ko, H.J.; Kim, J.K.; Véniant, M.M. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes, 2009, 58(1), 250-259.
29. [29] Hecht, R.; Li, Y.S.; Sun, J.; Belouski, E.; Hall, M.; Hager, T.; Yie, J.; Wang, W.; Winters, D.; Smith, S.; Spahr, C.; Tam, L.T.; Shen, Z.; Stanislaus, S.; Chinookoswong, N.; Lau, Y.; Sickmier, A.; Michaels, M.L.; Boone, T.; Véniant, M.M.; Xu, J. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes. PLoS One, 2012, 7(11), e49345.
30. [30] Harmer, N.J.; Pellegrini, L.; Chirgadze, D.; Fernandez-Recio, J.; Blundell, T.L. The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry, 2004, 43(3), 629-640.
31. [31] Fukumoto, S. Actions and Mode of Actions of FGF19 Subfamily Members. Endocr. J., 2008, 55(1), 23-31.
32. [32] Micanovic, R.; Raches, D.W.; Dunbar, J.D.; Driver, D.A.; Bina, H.A.; Dickinson, C.D.; Kharitonenkov, A. Different roles of N- and C- termini in the functional activity of FGF21. J. Cell Physiol., 2009, 219(2), 227-234.
33. [33] Yie, J.; Hecht, R.; Patel, J.; Stevens, J.; Wang, W.; Hawkins, N.; Steavenson, S.; Smith, S.; Winters, D.; Fisher, S.; Cai, L.; Belouski, E.; Chen, C.; Michaels, M.L.; Li, Y.S.; Lindberg, R.; Wang, M.; Véniant, M.; Xu, J. FGF21 N and C termini play different roles in receptor interaction and activation. FEBS Lett., 2009, 583(1), 19-24.
34. [34] Cho, H.; Daniel, T.; Buechler, Y.J.; Litzinger, D.C.; Maio, Z.; Putnam, A.M.; Kraynov, V.S.; Sim, B.C.; Bussell, S.; Javahishvili, T.; Kaphle, S.; Viramontes, G.; Ong, M.; Chu, S.; Becky, G.C.; Lieu, R.; Knudsen, N.; Castiglioni, P.; Norman, T.C.; Axelrod, D.W.; Hoffman, A.R.; Schultz, P.G.; DiMarchi, R.D.; Kimmel, B.E. Optimized clinical performance of growth hormone with an expanded genetic code. Proc. Natl. Acad. Sci. USA, 2011, 108(22), 9060-9065.
35. [35] Pasut, G, Veronese, F.M. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev., 2009, 61(13), 1177-1188.
36. [36] Veronese, F.M.; Mero, A. The impact of PEGylation on biological therapies. BioDrugs, 2008, 22(5), 315-329.
37. [37] Kurfürst, M.M. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem., 1992, 200(2), 244-248.
38. [38] Abuchowski, A.; McCoy, J.R.; Palczuk, N.C.; van, Es. T.; Davis, F.F. Effect of covalent attachment of polyethylene glycol on im munogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 1977, 252(11), 3582-3586.
39. [39] Veronese, F.M.; Pasut, G. PEGylation, successful approach to drug delivery. Drug Discov. Today, 2005, 10(21), 1451-1458.
40. [40] An, Q.; Lei, Y.; Jia, N.; Zhang, X.; Bai, Y.; Yi, J.; Chen, R.; Xia, A.; Yang, J.; Wei, S.; Cheng, X.; Fan, A.; Mu, S.; Xu, Z. Effect of site-directed PEGylation of trichosanthin on its biological activity, immunogenicity, and pharmacokinetics. Biomol. Eng., 2007, 24(6), 643-649.
41. [41] Xu, J.; Bussiere, J.; Yie, J.; Sickmier, A.; An, P.; Belouski, E.; Stanislaus, S.; Walker, K.W. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem., 2013, 24(6), 915-925.
42. [42] Chaffee, S.; Mary, A.; Stiehm, E.R.; Girault, D.; Fischer, A.; Hershfield, M.S. IgG antibody response to polyethylene glycolmodified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest., 1992, 89(5), 1643-1651.
43. [43] Tsutsumi, Y.; Onda, M.; Nagata, S.; Lee, B.; Kreitman, R.J.; Pastan, I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA, 2000, 97(15), 8548-53.
44. [44] Kang, C.E.; Tator, C.H.; Shoichet, M.S. Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system. J. Control Release, 2010, 144(1), 25-31.
45. [45] Postic, C.; Dentin, R.; Girard, J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab., 2004, 30(5), 398-408.
46. [46] Badman, M.K.; Pissios, P.; Kennedy, A.R.; Koukos, G.; Flier, J.S.; Maratos-Flier, E. Hepatic fibroblast growthfactor-21 is regulated by PPAR alpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab., 2007, 5(6), 426-437.
47. [47] He, K.; Zhang, Y.K.; Ye, X.L.; Wang, W.F.; Cheng R.; Liu, M.Y.; Feng, M.F.; Xu, J.L.; Li, D.S. Stability and glucose regulation of FGF21 after modified with arginines. Prog. Biochem. Biophys., 2012, 39(11), 1089-1098.